Mercer Global Advisors
ALXN

Mercer Global Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Mercer Global Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,478
Closed -$3.03M – 1850
2021
Q2 		$3.03M Sell
16,478
-6,632
-29% -$1.14M 0.02% 446
2021
Q1 		$3.53M Sell
23,110
-1,585
-6% -$245K 0.03% 380
2020
Q4 		$3.86M Buy
24,695
+2,080
+9% +$267K 0.05% 268
2020
Q3 		$2.59M Sell
22,615
-1,117
-5% -$121K 0.04% 318
2020
Q2 		$2.66M Buy
23,732
+3,275
+16% +$348K 0.05% 269
2020
Q1 		$1.84M Buy
20,457
+18,582
+991% +$1.82M 0.04% 333
2019
Q4 		$203K Buy
+1,875
New +$201K ﹤0.01% 1080
2019
Q3 		– Sell
-1,530
Closed -$200K – 1219
2019
Q2 		$200K Sell
1,530
-62
-4% -$7.99K 0.01% 1056
2019
Q1 		$215K Buy
+1,592
New +$198K 0.01% 964

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Mercer Global Advisors's ALXN Position: Q3 2021 in Review

Mercer Global Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 16,478 shares — an estimated $3.03M sold.

Mercer Global Advisors first reported a position in ALXN in Q1 2019 and held it in 9 quarters. The position peaked at $3.86M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Mercer Global Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Mercer Global Advisors sold 16,478 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.03M.
  • Mercer Global Advisors first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Mercer Global Advisors's Alexion Pharmaceuticals position peaked at $3.86M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Mercer Global Advisors's 13F filing for Q3 2021, filed 10 Nov 2021.